Physician profile
James A Taylor
NPI 1124025283
$1,114.52
in general payments reported to CMS, 2019-2025
20 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.65 · 2020: $14.46 · 2021: $61.95 · 2023: $345 · 2024: $329 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $232.89 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $214.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $123.57 | 2019-2025 | |
| Abbott Laboratories | $75.30 | 2023-2024 | Freestyle Libre 3 |
| Abbvie INC. | $61.65 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $55.09 | 2023-2025 | Arexvy, Shingrix |
| Dexcom, INC. | $47.34 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $40.04 | 2021 | |
| Exact Sciences Corporation | $31.19 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.71 | 2020-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.49 | 2024 | Jardiance |
| Insulet Corporation | $24.97 | 2025 | Omnipod |
| Tris Pharma INC | $23.23 | 2023 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $21.91 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.67 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.85 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $18.70 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.66 | 2025 | Caplyta |
| Neos Therapeutics, LP | $15.63 | 2023 | Adzenys Xr-Odt |
| Acadia Pharmaceuticals INC | $13.65 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.